ArticleDiabetes research and clinical practice2023
Longitudinal trends in glycated hemoglobin during and after tuberculosis treatment.
Article in Diabetes research and clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Glycaemic trends, trajectories and control during TB treatment and its association with TB treatment outcome among patients with TB-diabetes multimorbidity.Pakistan journal of medical sciences · 2026Article
- Persistent Hyperglycaemia and Transient Dysglycaemia in Tuberculosis: Evaluating the Bidirectional Interaction With Type-2 Diabetes Mellitus and Clinical Outcomes.Tropical medicine & international health : TM & IH · 2026Article
- Diabetes screening among people with tuberculosis: a systematic review and meta analysis.EClinicalMedicine · 2026Article
- Adrenal and Metabolic Hormonal Axes Shape Anti-Tuberculosis Immune Responses in Human Immunodeficiency Virus-Tuberculosis Coinfection.Neuroimmunomodulation · 2026Review
- Tuberculous hyperglycaemia: a clinical, epidemiological and public health perspective.BMJ global health · 2025Article
- Cardiometabolic Biomarkers and Systemic Inflammation in US Adolescents and Young Adults With Latent Tuberculosis Infection: A Population-Based Cohort Study.Open forum infectious diseases · 2025Article
- Altered hepatic metabolic landscape and insulin sensitivity in response to pulmonary tuberculosis.PLoS pathogens · 2024Article
- Diabetes and tuberculosis: An emerging dual threat to healthcare.World journal of diabetes · 2024Article
- Prior tuberculosis, radiographic lung abnormalities and prevalent diabetes in rural South Africa.BMC infectious diseases · 2024Article
- Diabetes and tuberculosis syndemic in India: A narrative review of facts, gaps in care and challenges.Journal of diabetes · 2024Review
- Associations between type 1 diabetes and pulmonary tuberculosis: a bidirectional mendelian randomization study.Diabetology & metabolic syndrome · 2024Article
- Variations in Quinolinic Acid Levels in Tuberculosis Patients with Diabetes Comorbidity: A Pilot Prospective Cohort Study.Infection and drug resistance · 2024Article
- Prevalence trends, population characteristics and treatment outcomes of tuberculosis combined with diabetes in Southwest China: a register-based retrospective study.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
aimsTo investigate the impact of pulmonary TB on glycemic status during and after TB treatment, and associations of glycemic trends with antidiabetic therapy and TB outcomes.
methodsData from two prospective cohort studies of adults in Chennai, India, with pulmonary TB were combined for this analysis. Participants were classified by baseline hemoglobin A1
resultsMedian A1C at baseline declined after TB treatment initiation in all groups. No baseline NG or pre-DM participants progressed to DM by end of study, while 16.7% of baseline DM participants shifted to pre-DM or NG levels of A1C. In the baseline DM group, rising A1C after the intensive phase of TB treatment was significantly associated with adverse TB outcomes.
conclusionsIncident TB promotes transient glucose elevation but was not conclusively shown to promote chronic dysglycemia. Rising A1C during and after TB treatment may predict unfavorable treatment response in persons presenting with A1C ≥ 6.5 % at the time of TB diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.